Jiangxi and Hunan provinces, many national varieties have completed the full-year indicators.

Pharmaceutical Network August 4th, the implementation of the national harvest for half a year, Jiangxi Province, Hunan Province this week informed the state organization of centralized procurement and use of drugs, although only half a year, there are many varieties have completed the whole year procurement volume.
, Jiangxi Province, July 29, Jiangxi Province informed the implementation of the state organization of drug centralized procurement and use of the "briefing", two batches of national results data as of June 30.
the first batch of national procurement (state-organized drug centralized procurement and use of the pilot expansion) Jiangxi results 25 drugs from December 20, 2019 in the province, the second batch of state-organized drug centralized procurement and use of Jiangxi's results 32 drugs from April 11, 2020 in the province.
the first batch of national harvest: (i) procurement quantity.
31 of the 25 drugs purchased in 12 Union areas of the province for a total of 28,706.98 million tablets/branches/bags. according to the
, the highest was 47.3939 million tablets of Ebeshatan 75mg and the lowest was 0.29 million of the 500mg of Permeycse.
(ii) the purchase amount. the total amount of procurement in the province of
31 product regulations was RMB26,281,800, accounting for 57.54% of the purchase amount of the same standard drug.
, the highest was $5799.97 million for clopidogrel 75mg and $948,000 for the lowest 10mg in Renopry.
(iii) complete the progress.
31 product regulations of the province's total procurement volume accounted for 136.9% of the total agreed procurement, 24 product regulations completed the province's agreed procurement quantity, 6 product regulations completed 75%, 1 product regulation completed 50%.
(iv) the proportion of drugs selected. the total quantity of procurement in the province of the
31 standards accounted for 87.08% of all drug purchases under the same regulations, and by drug statistics, the highest was 98.9% of the 100mg of Permeycse and the lowest was 73.79% of the 20mg of Atorvastatin.
(v) online distribution rate.
the total number of purchase orders in the province of 31 standards was 40,957.08 million pieces/branches/bags, and the number of online distributions of enterprises was 30,525.19 million pieces/pieces/bags, with a distribution rate of 74.53 percent. according to the
, according to drug statistics, there are three standards of delivery rate of less than 60%, respectively, resuvastatin 5mg 42.04%, tenofovir 300mg 46.02% and Rishuavastatin 10mg 53.98%.
.
the second batch of national harvest: (i) the quantity purchased.
36 of the 32 drugs purchased in 12 union areas of the province totalling 10,382.21 million tablets/branches/bags;
(ii) the purchase amount. The total amount of the province's procurement of 36 product regulations
was RMB373.02 million, accounting for 61.14 per cent of the purchase amount of the same standard drug.
according to drug statistics, the highest injection of yew alcohol (albumin binding type) 100mg of 985.76 million yuan, the lowest 2.5 mg of bislore 10 million yuan.
(iii) complete the progress.
36 product regulations of the province's total procurement volume accounted for 82.36% of the total agreed procurement, 11 product regulations completed the province's agreed procurement quantity, 17 product regulations to complete the progress of more than 50%.
(iv) the proportion of drugs selected.
the total quantity of the province's procurement of 36 standards accounted for 86.2% of the total quantity of all drugs purchased under the same regulations, and the proportion of 5 standards was lower than the prescribed proportion, namely, Amoxicillin 0.25g/0.5g, Pesorol 2.5mg, Azimycin 0.25g and Kandysataneste 4mg.
(v) online distribution rate. the total purchase order of the province of
36 product regulations was 13.31855 million pieces/branch/bag, and the number of online distributions of enterprises was 107.1676 million pieces/pieces/bags, with a distribution rate of 80.46 percent.
has a distribution rate of less than 60% for 6 standards, namely Amoxilin 0.5g, Amison Tan 5mg, Omesatin ester 20mg, Gremeyre 2mg, Meloxicon 7.5mg and Qumethlon 35mg.
On July 31, Hunan Province, the Health Insurance Bureau announced the implementation of the first batch of national procurement in Hunan Province as of June 30, 2020, and agreed to complete the purchase volume as follows: 25 selected drugs, the total amount of planned procurement in Hunan Province was 23,192.54 million (slices, grains), and the total amount of planned procurement was 180.168 million yuan.
as of June 30, 2020, the actual purchase amount was RMB 32.234.82 million, and the provincial average procurement execution progress was 86.07% (in terms of purchase quantity).
of which "Rainopry" and other 10 selected drugs have completed the full-year planned purchase volume, "Paroxitin" and other 4 selected drugs agreed purchase volume completion progress is less than 50%; The average procurement and implementation progress of provincial medical institutions was 43.18 percent, of which the fastest progress was the Hunan Provincial Mining Hospital, the progress was 100%, the slowest was the Hunan Children's Hospital, the progress was only 20.10% (details see schedule) Hunan Province also reported some problems: (a) the drug payment settlement is not timely part of the medical institutions default on drug payments prominent, especially in the primary medical institutions more common.
analysis mainly has the following reasons: First, medical institutions subjectively did not seriously implement the policy requirements, some local medical insurance departments supervision and restraint is not enough, the role of discipline did not play.
is to some extent affected by the outbreak of new crown pneumonia.
third is that some primary medical institutions need to go through the local accounting center, the settlement approval process is relatively complicated.
(ii) The progress of drug collection is not balanced, the progress of the work of the cities and states is not balanced.
analysis mainly has the following reasons: First, the local health insurance sector work supervision is not strong enough, collection policy publicity and guidance efforts need to be strengthened.
second is that some medical institutions are not strong sense of responsibility, procurement personnel are not familiar with the volume procurement business operating procedures.
third, affected by the outbreak of new crown pneumonia, medical institutions in-patient, outpatient business decreased significantly, affecting the procurement and use of selected drugs.
Fourth is that some medical institutions did not dock the selected drug distribution enterprises in time, the selected drugs were not included in the hospital procurement in time.
Five is some medical institutions reporting errors, the actual demand and agreed procurement volume gap is large, resulting in low statistical indicators.
the uneven completion of the progress of the selected drugs.
some medical institutions did not actively promote the clinical replacement of selected drugs as required, still a large number of procurement, the use of non-selected varieties under the generic name or pharmacological effects of similar other varieties, resulting in the procurement of selected drugs, the use of slow progress.
or in order to complete the assessment indicators, only a short period of time centralized procurement, the use of selected drugs, not only to promote the collection of land, rational drug use implementation has a negative impact, but also not conducive to the internal management of medical institutions, pharmaceutical departments and clinical good relations of cooperation.
in addition, Xiangya Three Hospital and other medical institutions to adopt pharmacists into the ward and other models, in-depth clinical to doctors, patients preach collection policy, introduce the collection of drugs, actively promote policy implementation and clinical guidance, forming a better atmosphere for the use of drugs, all places can be combined with practical positive reference.
(3) Some medical institutions have not yet started procurement as of June 30, 2020, individual medical institutions that have reported no record of procurement of selected drugs, please the medical insurance departments at all levels attach great importance to actively find the reasons, timely promote related work.
.